Pacira BioSciences, Inc.

Pacira BioSciences held its 2026 Annual Meeting, where stockholders elected all three of the company's director nominees and approved the Amended and Restated 2014 Employee Stock Purchase Plan, authorizing an additional 800,000 shares. However, stockholders rejected the Amended and Restated 2011 Stock Incentive Plan. The board also restructured committee compositions, and KPMG LLP was ratified as the independent auditor.

Pacira BioSciences announced that Glass Lewis & Co., LLC, a leading independent proxy advisory firm, has recommended that Pacira stockholders vote "FOR" all three of Pacira's director nominees and "AGAINST" all three of DOMA Perpetual Capital Management LLC's nominees. Glass Lewis cited Pacira's actionable 5x30 plan designed to deliver substantial stockholder value by 2030, supported by a 37% one-year total stockholder return in 2025 and a 23.8% cumulative return since the strategy's launch. The firm also noted the Company's new pipeline products and efforts to protect intellectual property, while questioning DOMA's nominees' skills and alignment.

Pacira BioSciences urged stockholders to vote for its board nominees (Christopher Christie, Samit Hirawat, MD, and Thomas Wiggans) at the upcoming Annual Meeting on June 9, 2026, amidst a proxy contest initiated by DOMA Perpetual Capital Management LLC. The company highlighted its "5x30 strategy" and strong 2025 financial performance, including record total revenues of $726.4 million and non-GAAP net income of $122.3 million. Pacira also emphasized the favorable EXPAREL settlement, which provides exclusivity into 2030, and its refreshed board's commitment to stockholder engagement.

Pacira BioSciences, Inc. announced its participation in three upcoming analyst-led fireside chats at healthcare conferences. The company will present at the 2026 RBC Capital Markets Global Healthcare Conference on May 20th, the 2026 Jefferies Global Healthcare Conference on June 3rd, and the Goldman Sachs 47th Annual Global Healthcare Conference on June 8th. Live audio and webcast replays will be accessible via the company's investor relations website.

Pacira BioSciences sent a letter to stockholders ahead of its 2026 Annual Meeting, urging them to vote for its three highly qualified director nominees: Christopher Christie, Samit Hirawat, MD, and Thomas Wiggans. The company highlighted its nominees' extensive experience in healthcare and biopharmaceuticals, crucial for overseeing its 5x30 strategy. Pacira strongly criticized DOMA Perpetual Capital Management LLC's director candidates as underqualified and their proposed plan as misguided, potentially leading to value destruction. The company recommends using the BLUE proxy card and disregarding any white proxy card from DOMA.

Pacira BioSciences, Inc. announced the granting of inducement awards to ten new employees on May 4, 2026, under its Amended and Restated 2014 Inducement Plan. These awards, approved by the People & Compensation Committee, include stock options for 36,800 shares to three employees and restricted stock units for 27,700 shares to ten employees, serving as a material inducement for their employment.

Pacira BioSciences reported strong first-quarter 2026 results, with revenue increasing 5% to $177 million and Adjusted EBITDA reaching $40.2 million. The company highlighted the successful execution of its 5x30 strategy, which has seen its stock rise over 30% since its January 2025 launch, and reiterated its board's unanimous recommendation for its highly qualified nominees in the upcoming annual meeting. Pacira also announced $50 million in share repurchases during Q1, retiring approximately 2.2 million shares, and detailed progress across its product portfolio and pipeline, including significant growth in ZILRETTA and iovera° sales.

Pacira BioSciences, Inc. reported Q1 2026 total revenues of $177.4 million, an increase from $168.9 million in Q1 2025. However, net income decreased to $2.9 million ($0.07 EPS) from $4.8 million ($0.10 EPS) in the prior year period. The company also engaged in significant financing activities, including a $50.0 million treasury stock buyback and a $5.0 million repayment of its Revolving Credit Facility.

Pacira BioSciences reported Q1 2026 total revenue of $177.4 million, a 5% increase year-over-year, driven by growth across its commercial portfolio, including 7% EXPAREL volume growth. GAAP net income decreased to $2.9 million ($0.07 per share) from $4.8 million ($0.10 per share) in Q1 2025. The company also repurchased 2.2 million shares for $50.0 million and reiterated its full-year 2026 financial guidance. Additionally, Pacira completed enrollment in its Phase 3 ZILRETTA study for shoulder osteoarthritis, with topline results expected by year-end.

Pacira BioSciences reported Q1 2026 total revenue of $177.4 million, a 5% increase year-over-year, driven by growth across its commercial portfolio, including EXPAREL volume growth of 7%. GAAP net income was $2.9 million ($0.07 per share), while non-GAAP net income was $24.5 million ($0.60 per share). The company completed enrollment in its Phase 3 registrational study for ZILRETTA in shoulder osteoarthritis, with topline results expected by year-end. Pacira also repurchased $50.0 million of common stock and reiterated its full-year 2026 financial guidance.